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Background: Osteosarcoma (OS) is an aggressive and often fatal cancer that afﬂicts over 1000 humans
and 10,000 dogs per year in the United States. Recent evidence suggests deregulation in the signaling
triad, receptor activator of nuclear factor kappa B (RANK), its activating ligand (RANKL), and the RANKL
inhibitor, osteoprotegerin (OPG) plays a key role in the pathogenesis of OS. This study investigated the
expression of RANK and RANKL in osteosarcoma tumors and cell lines and describes an activating effect
of OPG on OS cells in vitro.
Results: Canine OS tumors and cell lines co-express mRNA for both RANK and RANKL. Expression of
these proteins in OS cell lines was conﬁrmed by Western blot and immunoﬂuorescence microscopy.
Expression of the soluble form of RANKL was not detected in media from OS cells. OPG-Fc incubation
increased the phosphorylation status of ERK, AKT and the p65 subunit of nuclear factor kappa B (NFκB)
and induced NFκB translocation from the cytoplasm to the nucleus in canine OS cells. OPG increased
proliferation in both canine and human derived OS cell lines.
Conclusion: RANKL is produced by OS tumors and cell lines that also express RANK. This data provides
preliminary evidence for a potential autocrine and or paracrine activation pathway in canine OS. An
activating effect of exogenous OPG on signal transduction proteins, NFκB and proliferation in OS is de-
scribed. These data provide new information concerning aberrant signaling in OS and could be important
to those considering OPG as a therapeutic agent for osteosarcoma.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS) is an aggressive, highly invasive bone tumor
of mesenchymal origin [1]. It is characterized by cells with os-
teoblastic differentiation, poorly deﬁned borders and cortical de-
struction that results in bone pain and compromised structural
integrity [1,2]. The neoplasm typically arises in a long bone, grows
rapidly, and causes early death through metastasis in dogs. Ac-
celerated resorption of bone at the tumor site results in the release
of growth factors and cytokines that accelerate tumor progression,
vascularization and metastatic potential. The major sites of me-
tastasis are the lungs [3–5].
Because OS occurs more frequently in dogs, its presence in dogs
provides a convenient and relevant model for the development of
new therapies that may be effective for the treatment of OS inInc. This is an open access article u
K. Marley),humans [6]. In particular, access to a large number of dogs with OS
provides a model system from which an improved understanding
of the roles of Receptor Activator of Nuclear Factor κB Ligand
(RANKL), and its negative regulator osteoprotegerin (OPG) may be
developed [7]. In healthy bone, RANKL is necessary for osteoclast
differentiation and regulates osteoclast-mediated bone resorption
[8,9]. Blocking RANKL, which exists in both membrane-bound and
soluble forms, results in osteoclast death by apoptosis [10]. While
RANKL is necessary to osteoclast differentiation, function and
survival, the role of RANKL signaling in OS is not well understood.
Aberrant production of RANKL by tumor cells may be re-
sponsible for the increased osteoclast number and activity found
in both primary and metastatic osteolytic tumors [11]. RANKL has
been shown to be expressed in a variety of tumor types including
canine osteosarcoma [12] and is implicated in metastasis [13] and
tumor progression in several human cancers [11]. These and other
studies suggest RANKL may be a critical mechanism by which
tumor cells abnormally increase bone resorption [7] and this has
led to the idea that OPG could potentially attenuate this effect in
osteolytic tumors.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
FS¼ female spayed, MN¼male neutered.
Case ID Breed Sex Age Weight Location
A Old English Sheepdog FS 5 yrs 31 kg Distal radius
B Golder Retriever mix MN 9 yrs 34 kg Ulna
C Rottweiler MN 10 yrs 52 kg Rib
D Doberman mix MN 4 yrs 32 kg Distal tibia
E German Shepherd mix MN 6 yrs 24 kg Proximal tibia
F Labrador Retriever MN 9 yrs 35 kg Distal tibia
G Labrador Retriever MN 6 yrs 41 kg Distal radius
H Rottweiler FS 7 yrs 29 kg Distal radius
I Boxer FS 10 yrs 23 kg Proximal humerus
J Pug MN 11 yrs 8 kg Ulna
K. Marley et al. / Experimental Cell Research 338 (2015) 32–38 33In one study, OPG inhibited tumor progression, osteolysis and
osteoclast number in a mouse model of osteosarcoma [5] but other
reports describe a protective/permissive effect of OPG in breast,
[14], prostate [15] and myeloma cells in vitro [16]. These studies
provided evidence for an indirect effect of OPG through binding of
TNF-related apoptosis inducing ligand (TRAIL) and OPG was
shown to reduce TRAIL-induced apoptosis in cultured cells. Others
have shown that OPG is involved in tumor-related angiogenesis
[17] and increased OPG expression has been correlated with tumor
grade in breast cancer tissue biopsies [18] but few studies have
reported a direct effect of OPG on cell function. In this regard,
Kobayashi-Sakamoto et al. reported that incubation with OPG ra-
pidly phosphorylated extra-cellular related kinase (ERK) and focal
adhesion kinase (FAK) and enhanced invasion in endothelial cells
in vitro [19]. Others have described a direct effect of OPG on human
osteoblastic and ovarian cancer cells [20,21] suggesting OPG has
multiple physiologic actions that have yet to be elucidated.
The current study describes the expression of RANK and RANKL
in canine OS tumors and cell lines. Further, we describe an ap-
parent paradoxical activation of proliferation and phosphorylation
of cytoplasmic signal transduction proteins including the tran-
scription factor nuclear factor kappa β in OS cells treated with
OPG.2. Methods
2.1. Cell culture
One human and four canine OS cell lines were used in this
study. The canine cell lines included D17 (ATCC CCL183), Clone 48-
4, [22], COS [23], and POS [24]. The human OS cell line (Saos-2)
was purchased from American Type Culture Collection Co. (Man-
assas, VA). Cells were cultured at 37 °C in a humidiﬁed 5% CO2
atmosphere in RPMI 1640 (Invitrogen) supplemented with 2 mM
glutamine, 2 mM sodium pyruvate, 2 mM HEPES, 1% pen-strep,
and 10% fetal bovine serum (from here forward referred to as R10).
An osteoprotegrin–immunoglobulin Fc (OPG-Fc) fusion protein
produced in yeast containing the below sequence was obtained
commercially (GenWay Biotechnology, San Diego) and suspended











Tumor samples were collected from dogs with naturally oc-
curring OS (Table 1). Tumors were excised by amputation, during
limb salvage surgery, or rib excision and samples were held on ice
in RPMI 1640 then rinsed with sterile saline and preserved in an
RNA stabilization solution according to the manufacturer's in-
structions (Ambion, #AM7020).
2.3. PCR
RNA was extracted from cells and tumors using a spin column
extraction kit according to the manufacturer's directions (Qiagen
#74106). Brieﬂy, cells were grown to 80% conﬂuence, then rinsed in
cold PBS, scraped, transferred to microcentrifuge tubes and pelletedin a centrifuge (5 min, 300xg). The supernatants were discarded and
the cell pellets were re-suspended in “RLT extraction buffer”, soni-
cated four times (1 s each) using an ultrasonic dismembranator
(Fisher, Model 150T) and cleared by centrifugation (10,000xg) prior
to loading the supernatants on individual extraction columns. RNA
was extracted from tumor tissue that had been pulverized under li-
quid nitrogen using the same procedure except that pulverized fro-
zen tissue was suspended directly in “RLT buffer” (Qiagen #74106).
Puriﬁed RNA was eluted in sterile water and concentrations were
measured by spectrophotometry (Thermo Scientiﬁc, ND-1000). One
mg of each RNA sample was converted to cDNA by reverse tran-
scription as directed (Applied Biosystems, kit #4368814). Standard
PCR was used to amplify signals for RANK and RANKL using the
following primers RANK forward; GCGTGAAATTTGTGATGGTG, and
reverse; GGCTCTCTGTCCCAGTGAAG (product¼346 bp), and RANKL
forward, CTGGTACCATGACCGAGGTT; and reverse, AACTCGG-
GATTTTGATGCTG (product¼196 bp). PCR products were separated
by electrophoresis using 1.5% agarose with added ﬂuorescent dye
(Invitrogen #33102) for visualization. PCR products were puriﬁed
using a magnetic bead method (Invitrogen CS12000) prior to se-
quencing on an ABI Prisms 3730 Genetic Analyzer.
2.4. Western blots
Cells grown in 75 cm2 ﬂasks to approximately 80% conﬂuence
were rinsed in ice cold PBS, removed with a cell scraper, and
pelleted in a tabletop centrifuge (3 min, 1200 x g). Proteins were
extracted either directly from whole cell pellets, or from cyto-
plasmic/nuclear separations using 50 ml of ice cold RIPA buffer
with protease and phosphatase inhibitor cocktails (Sigma). Cyto-
plasmic and nuclear extractions were performed using a com-
mercial kit as directed (Invitrogen, #78835). After solubilization in
RIPA buffer, the extracts were sonicated four times (1 s each) using
an ultrasonic dismembranator (Fisher, Model 150T) and pelleted at
10,000xg to remove cellular debris. Protein concentration was
measured in triplicate using a commercial kit (Pierce, BCA). Pro-
teins (20 mg/lane) were separated on 4–12% SDS polyacrylamide
gels and transferred to PVDF membranes using standard methods.
The membranes were blocked in 1.5% albumin in TTBS and reacted
with indicated primary antibodies diluted 1:400 overnight at 4 °C
(antibodies from Santa Cruz Biotechnology (SCBT); RANK, sc-
34249; RANKL, sc-9073; AKT, sc-1619; pAKT, sc-33437; ERK, sc-93;
pAKT, sc-7383; p65, sc-109; pP65, sc-101752). A recombinant form
of soluble RANKL was used as a positive control for Western blots
(Genway Biotechnology #GWB-B354EC). The membranes were
washed, reacted with horseradish peroxidase-linked secondary
antibody (SCBT, sc-2005) diluted 40,000:1, exposed to substrate
(ECL Select, GE Healthcare) and imaged using a digital imaging
system (Image Quant LAS 4000, GE Healthcare). Signals from di-
gital images were assessed for band density using Image Quant TL
software (GE Healthcare). Density values (arbitrary units) were
K. Marley et al. / Experimental Cell Research 338 (2015) 32–3834normalized in order to present data in histogram form. Normal-
ization was accomplished by dividing the density values obtained
from the phosphorylated blot (untreated sample) by the values
from the total protein blot from the same sample. This baseline
value was used as a divisor of subsequent ratios to show changes
due to OPG-Fc treatment.
Example: density of p-AKT band¼2700
density of total AKT band¼5600
baseline ratio (2700/5600)¼0.4821
normalization untreated (0.4821/0.4821)¼1
Data presented are representative of at least two independent
experiments.
2.5. Immunoﬂuorescence
Cells grown on coverslips were rinsed with PBS then ﬁxed in a
50/50 solution of cold acetone and methanol for 60 seconds, al-
lowed to air dry, blocked in 1.5% albumin in TTBS (blocking buffer)
and reacted with indicated primary antibodies, or isotype controls,
diluted 1:50 in blocking buffer for 1 hour at room temperature
(antibodies from Santa Cruz Biotechnology; RANK, sc-34249;
RANKL, sc-9073). Normal mouse or rabbit IgG were used as isotype
controls for RANK and RANKL stained cells respectively (SCBT, sc-
2025, sc-3888). After blocking, the slides were rinsed in PBS and
incubated for 45 min at room temperature with ﬂuorophore-
linked secondary antibodies (anti-rabbit/mouse IgG) for detection.
(Santa Cruz Biotechnology, sc-2099 or sc-3917). Slides were rinsed
again with PBS, stained with dimethyl-formamide diluted to
100 ng/ml in PBS, to illuminate nuclei, cover-slipped and viewed
with a ﬂuorescence microscope with attached camera (Nikon
Eclipse ti). Slides stained with primary antibodies and isotype
controls had identical camera settings, exposure times and digital
processing. Images are representative of two independent
experiments.
2.6. Proliferation assay
The effects of OPG-Fc on cellular proliferation were determined
using the COS and SAOS-2 cell lines. Cells in R10 medium were
seeded in 96-well plates, at a density 5000 cells per well, and al-
lowed to adhere overnight. The medium was then replaced with
identical medium but without serum (Hereafter referred to as R0).
The cells were incubated for an additional 24 h in R0 medium
which was then replaced with fresh R0 containing either 0, 1.5, 3,
6 or 10 mg/ml OPG-FC. After 24 h incubation with OPG-Fc, cell
viability in triplicate wells was assessed using an MTS assay (Cell
Titer 96 One Solution Assay, Promega). RANKL/OPG-Fc combina-
tion incubations used 100 ng/ml RANKL and 10 mg/ml OPG-Fc in
R0 medium. Cells were incubated overnight in R0 prior to use and
the incubation periods were 48 h. RANKL was purchased com-
mercially (#6449-TEC-010, R&D Systems, Minneapolis, MN) and
suspended in sterile PBSþ0.5% albumin (Invitrogen) prior to use.
Absorbance was measured at λ¼490 following 60 min incubation
at 37 °C with the MTS product. Data presented are representative
of three independent experiments.
2.7. Invasion chamber assay
Invasion studies with the COS cell line were performed using
reduced growth-factor invasion chambers containing a membrane
with 8 mm pores (BD Biosciences, Bedford, MA) according to the
manufacturer's instructions. Brieﬂy, cells were seeded at a density
of 25,000/well into the top chamber in R0 medium. The bottom
chambers contained R10 medium. OPG-Fc was added to both the
top and bottom chambers, when appropriate, so the only differ-
ence between the top and bottom chambers was the 10% serum.After 24-h, the membranes were removed, stained with Diff Quik,
mounted on glass slides and imaged on a microscope. All cells that
had migrated through each membrane were counted and each
experiment was performed three times.
2.8. Statistics
Statistical comparisons using a one-way ANOVA with Tukey's
post hoc tests were performed, when appropriate, using Graphpad
Prism software (La Jolla, CA). Statistical signiﬁcance was set to
po .05 for all comparisons.3. Results
3.1. Expression of RANK and RANKL
The canine OS tumors and cell lines tested showed widespread
expression of both RANK and RANKL mRNA (Fig. 1A). Only one
tumor sample was negative for mRNA signal for either protein and
this was a rare telangiectatic osteosarcoma [25] (Table 1 and Fig. 1;
Case ID ‘A’). The results from the sequencing reactions using PCR
products from the COS cell line and tumor samples B–D matched
exactly with the published sequences for the canine RANK and
RANKL genes (NCBI gene ID; 483957 and 609418 respectively,
Fig. 1B). No mutations or single nucleotide polymorphisms were
noted in the sequenced regions (data not shown). RANK and
RANKL protein expression in 4 cell lines, shown by Western blot,
corroborates the mRNA data (Fig. 1C). Immunoﬂuorescence stain-
ing in 4 cell lines suggests RANK and RANKL proteins are co-ex-
pressed in the same cell (Fig. 2).
3.2. Activating effects of OPG-Fc
Our ﬁndings of widespread RANK and RANKL expression in
canine OS led us to hypothesize the expression of the soluble form
of RANKL might act as a paracrine or autocrine signal that could
drive tumor growth. Further, we hypothesized this mechanism
might represent an option for therapeutic intervention because
OPG is a commercially available drug. In this regard, we were
unable to detect the soluble form of RANKL in conditioned media
using commercially available ELISA kits (Amsbio, Cambridge,
#E08R0005: RnDSystems, Minneapolis, #MTR00, data not shown)
or by Western blot (Fig. 1D). Having detected no evidence of so-
luble RANKL, we speculated the membrane form of RANKL could
potentially retain the ability to bind its receptor through cell-to-
cell contact. Consequently we attempted to inhibit this signal
using OPG-Fc. The activating effect of OPG-Fc on proliferation in
these cells is shown in Fig. 3. After only 24 h incubation, the cells
exposed to OPG-Fc were visually more dense (data not shown) and
the MTS assay shows a dose response relationship (po .05) in the
COS cell line for every data point up to and including the highest
concentration tested (10 mg/ml, Fig. 3A). Fig. 3B shows a similar but
less pronounced effect of OPG-Fc on Saos-2 cells.
3.3. Mechanisms of OPG-Fc stimulation
Western blots, using whole cell lysates and lysate proteins from
the COS cell line that had been separated into cytoplasmic and
nuclear fractions, were used to begin to describe the mechanisms
of action of OPG-Fc in canine OS. The cytoplasmic signal trans-
duction proteins AKT and ERK both showed an increase in phos-
phorylation after 30 min incubation with OPG-Fc (Fig. 4). Histo-
gram representation of densitometry data from the Western blots
shown in Fig. 4A shows OPG-Fc incubation caused a 4–5 fold in-






















Fig. 1. RANK and RANKL expression in canine osteosarcoma. A) PCR ampliﬁcations of RANK and RANKL transcripts indicate strong expression in both OS cell lines and
primary tumors. Signalment for patients A through J are shown in Table 1. B) PCR products were sequenced and, in all cases, conﬁrmed homology with published sequences
(NCBI gene IDs; 483957 and 609418). C) Western blots from OS cell lines conﬁrm protein expression of RANK and RANKL. D) The soluble form of RANKL was not detected in






Fig. 2. Immuno-ﬂuorescence. Cells stained with green- (FITC) and red- (TRITC) secondary linked ﬂuorophores show co-expression of RANK and RANKL respectively. The
merged images include blue-stained nuclei. The orange color indicates where RANK and RANKL appear co-expressed. Bars equal 10 μm. There was mild positive signal
(green) from the isotype control sera matching the RANK primary antibody (data not shown).(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
K. Marley et al. / Experimental Cell Research 338 (2015) 32–38 35the cytoplasm (Fig. 4B). ERK and AKT were found in both the cy-
toplasmic and nuclear fractions and the pattern of increased
phosphorylation was similar in the nuclear fractions but of smaller
magnitude (Fig. 4B). Nuclear/cytoplasmic separations were carried
out because NFkB moves, when activated, from the cytoplasm to
the nucleus. This study used the P65 sub-unit of NFkB as an in-
dicator of NFkB activity. The Western blot data shown in Fig. 4suggests total P65 protein declined in the cytoplasm after 30 min
exposure to OPG-Fc but the expected concomitant increase in
nuclear P65 was not observed at this time point. Consequently we
increased the OPG-Fc incubation time to 24 h. After 24 h, the cells
exposed to OPG-Fc showed a slight decrease in total P65 Western
blot signal in the cytoplasmic fraction and a dramatic increase in
the nuclear fraction suggesting the protein was activated and



































Fig. 3. OPG-Fc stimulates proliferation. COS (A) and Saos-2 (B) cells incubated in
serum-free medium then exposed to varying concentrations of OPG-Fc show a
dose-dependent increase in proliferation. * indicates different from control
(Po .05). Incubations were for 24 h.
K. Marley et al. / Experimental Cell Research 338 (2015) 32–3836transported from the cytoplasm to the nucleus (Fig. 5A and B). A
dramatic increase in the phosphorylated form of P65 was also
observed in the nuclear fraction (Fig. 5B) providing strong evi-
dence that OPG-Fc activates P65 and induces its transport to the
nucleus.3.4. Effects of OPG-Fc on invasion
Others have shown that OPG acts through αv integrins to in-
duce invasion in endothelial cells [26]. This effect was notFig. 4. Short exposure to OPG-Fc induces tyrosine phosphorylation and activates NFkB.
transduction proteins ERK and AKT in the cytoplasm and nucleus and a reduction in total
increased in the nucleus but loading control blots for this protein were not successful. D
blots shown in ‘A’ are presented for clarity as the ratio of the phosphorylated form norobserved in COS cells exposed to 2 mg/ml OPG-Fc (Fig. 6A). Higher
concentrations were not tested.
3.5. Effects of RANKL alone and in combination with OPG-Fc on
proliferation
RANKL alone (100 ng/ml) had no apparent effect on prolifera-
tion in the COS or Saos-2 cell lines (Fig. 6B). Proliferation was not
different between cells incubated with OPG-Fc alone and cells
incubated with OPG-Fc/RANKL combined.4. Discussion
The osteolytic invasion that characterizes OS may be driven by
RANKL-producing tumor cells that activate NFκB in osteoclasts
and drive their development and function. The resulting de-
gradation of bone likely causes the release of sequestered growth
factors to create a feed-forward loop [27]. The potential down-
stream consequences of this cascade of events are numerous and
the literature contains multiple references to the effects of aber-
rant activation of the NFκB pathway in tumor cells. These include
proliferation, invasion, angiogenesis, inﬂammation and metastasis,
many of which are hallmarks of malignant cancer [28,29]. This
study describes widespread expression of RANK and RANKL in
canine OS tumors and cell lines however, the function of these in
OS has not been determined. Alternative tests such as, siRNA
knockdown of RANK, are needed to further elucidate the im-
portance of the co-expression of RANK and RANKL in OS.
Novel information suggesting incubation with OPG-Fc phos-
phorylates signal transduction proteins, activates NFκB and sti-
mulates the growth of OS cells in vitro is presented. A recent
ﬁnding that OPG is elevated in the serum of human patients with
malignant or benign bone tumors [30] suggests OPG could be one
component of a complex system that drives bone tumor growth.
Kobayashi-Sakamoto and colleagues showed OPG activates Src and
FAK in endothelial cells and suggest this mechanism may be re-
levant to tumor angiogenesis, vascular disease and periodontitis
[19]. Similar to other published studies [19], the OPG concentra-
tions required to elicit a signiﬁcant response in the current work
were higher than could be achieved pharmacologically. None-
theless, the current study provides additional informationA) Western blots using proteins extracted from COS cells show activation of signal
P65 in the cytoplasm of cells treated with OPG-Fc for 30 min. Phospho-PI3K appears
ata represent at least two independent experiments. B) Densitometry values from
malized against the total protein signal from the same experiment (see Section 2).
Fig. 5. Long exposure to OPG-Fc induces changes in NFκB. A) Western blots from
COS cells incubated with OPG-Fc for 24 h show an increase in the phosphorylated
form of the P65 subunit of NFκB in the nucleus but not in the cytoplasm. B) Den-
sitometry values shown are normalized against the total protein signal (see Section
2). C) Densitometry data from the Western blot shown in ‘A’ indicate P65 moved
from the cytoplasm to the nucleus in response to OPG-Fc treatment. Values are
normalized to the untreated controls. Data are representative of at least two in-
dependent experiments.












Fig. 6. A) OPG-Fc does not increase COS cell invasion. Cell counts from 24 h inva-
sion assays show the mechanism of OPG-Fc action does not strongly increase in-
vasive behavior in this cell line. B) Incubation with 100 ng/ml RANKL had no ap-
parent stimulatory effect on proliferation. Proliferation values from cells incubated
with the combination of OPG-Fc and RANKL were not different from those treated
with OPG-Fc alone p4 .05. nIndicates diff from control. Dark and grey bars indicate
Saos-2 and COS cell lines respectively.
K. Marley et al. / Experimental Cell Research 338 (2015) 32–38 37concerning the OPG activation pathway and suggests OPG signal-
ing could culminate in the phosphorylation and transport of NFκB
from the cytoplasm to the nucleus. Whether this is directly linked
to the expression or activation of RANK and RANKL remains to be
determined.
Both the membrane and soluble forms of RANKL are likely
capable of activating OS cells, however the soluble form was not
detected in the cells used in the present study. This could be be-
cause the soluble form is not produced in these cell lines, or be-
cause the conditions for its production are not replicated under
the current cell culture conditions. Additional tests using alter-
native model systems are likely needed to establish the sig-
niﬁcance of the current result.
The mechanism and conditions where RANK is activated
through membrane-bound RANKL is not well described. In this
regard, and based on a large body of literature suggesting the
primary function of OPG is to reduce RANK signaling, we sought to
block RANK activation using exogenous OPG-Fc. Thus we were
surprised to ﬁnd OPG-Fc activated rather than suppressed growth
in these cells. Lamoureux and colleagues described a suppressive
effect of OPG on tumor growth using gene transfer methods in twomodels of OS in rodents [5] however their report did not show a
direct effect of OPG on murine OS cells. In the current study, the
effects of OPG-Fc on two cell lines are described therefore no
generalization to OS is waranted and further studies are needed.
The present data describe a dramatic increase in OPG-induced
phosphorylation of AKT and ERK which suggests OPG either di-
rectly or indirectly activates a membrane bound receptor tyrosine
kinase upstream of these signaling proteins. Future efforts to
identify this receptor are warranted.
The lack of an observed growth stimulatory effect of 100 ng/ml
RANKL on the COS and Saos-2 cell lines suggests the receptor
RANK could be saturated, or not relevant to the proliferative
pathway in these cell lines. In this regard, Mori et. al. published
two papers in 2007 showing the same concentration of RANKL
(100 ng/ml) phosphorylates ERK and alters gene expression in
Saos-2 cells but no changes to proliferation, invasion or other
functions were observed [31,32]. The current data corroborates
these prior reports and provides new information showing that
OPG has pro-proliferative effects on OS cells that are independent
of RANKL.5. Conclusion
The co-expression of RANK and RANKL in OS may have im-
portant implications concerning the aggressive, fast growing and
metastatic nature of this neoplasm. The pro-proliferative effect of
OPG-Fc on these cells warrants further investigation in additional
OS cell lines and tumors.
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